Click here for Vyndaqel®▼ (tafamidis) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
This interactive resource highlights the red flags to look out for, such as the patients medical history in combination with diagnostic test results.
Hover your mouse over each section to learn more about the tests used to diagnose ATTR-CM, including additional clues to identify on echocardiograms, to heighten your suspicion of ATTR-CM.
This 8-page Leave Piece communicates the key signs to look out for to raise suspicion on ATTR-CM and which diagnostic tests need to be performed to confirm a diagnosis.
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Uncovering the Clues for Diagnosis. Downloadable PowerPoint Presentation to support peer-to-peer education. This presentation contains an overview of cardiac amyloidosis, ATTR-CM mechanism of disease, and how to assess suspicion and improve diagnosis of the disease.
Vyndaqel▼(tafamidis) for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). Downloadable PowerPoint Presentation to support peer-to-peer education. This presentation contains an overview of clinical trial data, safety information and dosing related to tafamidis.
Important information about Vyndaqel (tafamidis): A guide for Healthcare Professionals
See other educational resources available
Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.
PP-PFE-GBR-2809. October 2020
Sign up now
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020